title: Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.
abstract: BACKGROUND
  Predicting response to proton pump inhibitor (PPI) treatment can aid the effective management of gastroesophageal reflux disease (GERD). The aim was to investigate the predictors of symptomatic response to pantoprazole in Asian patients with GERD; the first study of its kind in Asian patients.
  
  
  METHODS
  Asian patients with GERD symptoms (N = 209) received pantoprazole 40 mg daily for 8 weeks in a multinational, prospective, open-label study. Response was assessed using ReQuest™. Baseline and demographic factors were examined using logistic regression to determine if they were related to treatment response.
  
  
  RESULTS
  Response rates were 44.3% (Week 4) and 63.6% (Week 8) in Asian patients versus 60.7% (P < 0.001) and 72.2% (P = 0.010) for the rest of the world. Higher response rates at 8 weeks occurred in patients with erosive reflux disease (ERD; 71.3%) versus those with non-erosive reflux disease (NERD) at baseline (48.5%). The presence of ERD (P = 0.0143) and lower ReQuest™-GI scores at baseline (P = 0.0222) were associated with response. Improvements in quality of life (QoL) and anxiety and depression at 4 and 8 weeks were associated with treatment response (both P < 0.0001). Patient satisfaction correlated with treatment response (P < 0.0001), and improvement in anxiety and depression (P < 0.0001) and QoL (P < 0.0001).
  
  
  CONCLUSIONS
  Asian patients with GERD, especially those with NERD, may have lower response rates to PPIs than Western populations. ERD and less severe gastrointestinal symptoms may help to predict symptomatic responses to PPIs in Asian patients.
  
  
  BACKGROUND
  ClinicalTrial.gov identifier: NCT00312806.
authors.forename: Khean Lee
authors.initials: KL
authors.lastname: Goh
authors.forename: Kee Don
authors.initials: KD
authors.lastname: Choi
authors.forename: Myung-Gyu
authors.initials: MG
authors.lastname: Choi
authors.forename: Tsai-Yuan
authors.initials: TY
authors.lastname: Hsieh
authors.forename: Hwoon-Yong
authors.initials: HY
authors.lastname: Jung
authors.forename: Han-Chung
authors.initials: HC
authors.lastname: Lien
authors.forename: Jayaram
authors.initials: J
authors.lastname: Menon
authors.forename: Steven
authors.initials: S
authors.lastname: Mesenas
authors.forename: Hyojin
authors.initials: H
authors.lastname: Park
authors.forename: Bor-Shyang
authors.initials: BS
authors.lastname: Sheu
authors.affiliation: The Chinese University of Hong Kong, Shatin, Hong Kong SAR, Republic of China. justinwu@cuhk.edu.hk.
authors.forename: Justin Cy
authors.initials: JC
authors.lastname: Wu
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D001007:Anxiety / Q000523:psychology; D044466:Asian People; D003863:Depression / Q000523:psychology; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D017060:Patient Satisfaction; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D011788:Quality of Life / Q000523:psychology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D000077402:Pantoprazole